Global Blood Therapeutics Inc (GBT) 시세

$GBT: August 19 $70 calls just shot up..... $0.40 to $6 !!!!!!!!


JUST LIKE THAT........ in just 20mins


Looks like the buyout rumors are about to play out after all


WOW


Last Post of the day................ $TMNA will be the BIGGEST WINNER



GO $GBT

Zacks Equity Research
Mon, December 20, 2021, 11:02 AM
In this article:

GBT
+2.32%

Explore the topics mentioned in this article

Global Blood Therapeutics, Inc. GBT announced that the FDA has granted accelerated approval to its supplemental new drug application (“sNDA”) for Oxbryta (voxelotor) to treat sickle cell disease (“SCD”) in children aged four to less than 12 years.

The regulatory body also approved the new drug application (“NDA”) for Oxbryta tablets for oral suspension – a new dispersible, once-daily tablet dosage for patients aged four to less than 12 years, as well as for older patients who have difficulty swallowing whole tablets.

Oxbryta is currently approved by the FDA as an oral, once-daily treatment for SCD in patients aged 12 years or above.

The FDA nod for the sNDA was based on data from the phase IIa HOPE-KIDS 1 study, which evaluated Oxbryta in the given patient population. Data from the same showed that weight-based treatment with the dispersible tablet formulation of Oxbryta led to rapid and sustained improvements in hemoglobin. Concurrent reduction of hemolysis or red blood cell destruction was also demonstrated in the study.

Shares of Global Blood have plunged 29.5% so far this year compared with industry’s decrease of 19%.

Sounds good

Priority reviews
https://finance.yahoo.com/news/u-fda-review-gbts-blood-120003810.html

Goldman Buy Today target 103 from 91

5 Best Mid-Cap Biotech Acquisition Targets

2019 Q4 has been a great quarter for biotech investors and more M&A deals are expected in 2020.

With the FDA approval of Oxbryta, GBT is the perfect acquisition candidate for treating sickle cell disease.

Global Blood Therapeutics (GBT) - $9B
With a market cap of $4.9B, Global Blood Therapeutics is engaged in the innovation and commercialization of drugs to serve the needs of sickle cell disease (NYSE:SCD). SCD is an inherited blood disorder caused by a genetic mutation in the beta-chain of hemoglobin, leading to the formation of abnormal hemoglobin known as sickle hemoglobin. GBT went up 60% over 3 weeks since the company confirmed FDA approval of Oxbryta (voxelotor), company's main drug to treat sickle cell disease in adults and children 12 years of age and older.

Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.

FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

Following suit, the European Medicines Agency (NYSEMKT:EMA) has also included voxelotor in its Priority Medicines (PRIME) program, while the European Commission (NYSE:EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD. Based on GBT's EHA corporate update in June, Oxbryta is addressing the needs of over 100,000 SCD patients in U.S. and 60,000 patients in Europe. The annual cost of SCD care is $200,000 per patient. An approved drug means R&D risks are largely absent and GBT is attractive to large Biopharma companies which seek to expand their drug pipelines without development risks.

Additionally, GBT started HOPE-KIDS2 which is to confirm there is a decreased risk of stroke for children 2 to 15 years old with Oxbryta. GBT also announced a collaboration with Syros Pharmaceuticals (SYRS) to discover, develop and commercialize novel therapies for sickle cell disease and beta thalassemia. On Dec 18, GBT secured $150M non-dilutive term loan to enhance its cash position for further development and commercialization, which clears any near-term dilution risks and places company in a great spot to negotiate a good deal with potential acquirers.

https://seekingalpha.com/article/4314536-5-best-mid-cap-biotech-acquisition-targets

Just keeps going up and up! making new highs each day !

What a day so far up over $3 to a new 52 week high of $80.45. Looks like Good news is coming for GBT!

Opinion: Biotech stocks are producing outsized gains — here’s how to get your share
Published: Dec 10, 2019 3:02 p.m. ET

New developments in clinical trials and drug approvals have become commonplace. And buyouts of biotech stocks at high premiums are increasing.

Here is how to get your share of the outsized gains that are being generated. Let’s explore the issue with the help of two charts.

Please click here for an annotated chart of Global Blood Therapeutics GBT, +1.25%.

Please click here for an annotated chart of the buyout of Tesaro by GlaxoSmithKline GSK, +0.15%. The acquisition was completed in January. For the sake of transparency, this chart was previously published.


https://www.marketwatch.com/story/biotech-stocks-are-producing-outsized-gains-heres-how-to-get-your-share-2019-12-09?siteid=yhoof2&yptr=yahoo

Global Blood Therapeutics: Oxbryta Is Aimed For Success

Excellent article.

One of the most exciting times for bioscience investors is during a positive regulatory binary, i.e. a drug approval. As I forecasted, Global Blood Therapeutics (GBT) gained FDA approval for its lead medicine, Oxbryta. Being the first of its kind, Oxbryta has a very strong chance of dominating an untamed market.

From a trading viewpoint, the stock usually but not always rallies after an approval. However, there are situations where the stock trades either sideways or lower. Regardless of the immediate or short-term event, a fundamentally strong company nearly always appreciates in the long haul. Either that or it'll get bought out to reward investors with a huge premium. In this article, I'll feature a fundamental update on GBT and provide my expectations for this intriguing growth equity.

In all, I maintain my buy recommendation on GBT with the four out of five stars rating. Riding the historic Oxbryta approval, GBT now has the best new medicine for SCD. Not only that Oxbryta has an excellent efficacy and safety profile, but it also is the only of its kind. As such, physicians are motivated to prescribe the drug when they know about it. That is to say when the marketing kicks in.

Now the SCD market is quite large, standing at approximately $3B without a dominant drug. As you see, Oxbryta is making its entry into this niche as a gamed "Apex predator." To be realistic, there are still crucial factors that can deter successful commercialization. While you don't have to agree with me, you should weigh the negatives and positives to gauge the long-term prospect of GBT.

Last but not least, two surprise catalysts can occur going forward. One is that GBT suddenly announced a marketing partner. Another possibility is a buyout. Either one would be a surprise present for the holiday.

Here is the entire article:

https://seekingalpha.com/article/4310396-global-blood-therapeutics-oxbryta-is-aimed-for-success

https://www.nytimes.com/2019/01/27/health/sickle-cell-gene-therapy.html

The unique statistics formula that has 83% accuracy predicting biotech data. Predict this upcoming GBT data to be a success.

insert-text-here

What turd! Company is going under

GBT buy 57.15

double bottom
new 52-week highs



















normal chart




log chart

$GBT Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results http://bit.ly/2h7OBks

https://seekingalpha.com/article/4115611-global-blood-therapeutics-drops-idiopathic-pulmonary-fibrosis-sickle-cell-disease-forefront

Since selling half my shares @ $37.50, I have reloaded and flipped x2 and now own x5 the shares I owned on 3/10/17. Should be a fun ride!!!

Between upcoming data points (adolescent SCD, IPF, & Ph3a) and impending B/O, pressure to the upside will begin to increase soon. Looking for a move into the $50's after June 24th data. May see $80's after IPF and Ph3a data presentations.

She is busting out now!
Sold half my shares today @ $37.50!

GBT bearish 17.50

What a beast

Well that was good for a pop to $27 .
Then sell the news , Co files a shelf , Brexit concerns, traders view no action for a year and now back to $18.
Life in Biotech.

A dead Board ...may be a good sign ..:>)

Looks like GBT is about to announce some impressive data on June 10th and has lined up an distinguished group of experts to discuss it .
Dr Bunn , from Harvard is the ( IMHO ) world expert in the field.
Doubt if he would be there unless the data was almost " break through " level .
GBT is also FDA Fast Tracked .
Farrow ( ex ZSPH ) is now the CFO .
Farrow has a lot of experience guiding Co's in Big Pharma buy outs

Kiwi

Movers and Shakers: The Week so Far - article mentions GBT

http://marketexclusive.com/movers-and-shakers-the-week-so-far/1142/

EPS= -1.51

There is not enough data on the chart for me to say any thing yet.
I use charts, not fundamentals.

Oh I see you posted a chart, pics from third party hosts don't show up for all users on iHub anymore bro, you need upload it to the site now.

I would like to know what your take is on this stock.

What do you want to know about ?
Do not under stand your question.
Need more details ?

What about it?

GBT daily chart

GBT D?

GBT D 4 MONTHS

Yeah not thrilled about it pricing $2 above $16-18 range either but sometimes it's a good thing. It indicates healthy demand and I am hearing multiple times oversubscribed. Sometimes it's best to just use a market order early, in my experience, and let the pros worry about buying dips or getting left behind. I'm more of a longterm holder anyway. I don't think it will drop drop to $15 though, too much demand and too small of a float.

I do think it has good potential long term with only 1 other major CSD competitor in BLUE so it's not like the market is saturated by any means. Look at what BLUE's stock price has done since it's IPO a couple years ago! Granted they have more in the pipeline and of course it's a different treatment with pills than with gene therapy but this could be a good one.

I tend to like the syndicates though. GS and MS usually back pretty good bio IPOs. Good luck tomorrow!

Worth 20? Not really sure, if thats it just a plain IPO with no news they think they can get 20 with not much revenue or earnings yet, seems greedy... will watch for movement beginning of day if I see a spike I in 5 minutes I will of course try but not sure about it.

The way biotech is running lately, I think anything could run 100%, its just valuation, 16 can certainly run to 32 but can 20 run to 40?

Maybe the play is wait and see, if it drops to 15 then thats cheap, grab the dip and then retail catches up to it might run to 25, that would be sweet.

By the way thank you for the message board protagonist12!

Global Blood Therapeutics, an early-stage biotech developing a small molecule therapy for sickle cell disease, raised $120 million by offering 6.0 million shares at $20, above the range of $16 to $18. Global Blood Therapeutics plans to list on the Nasdaq under the symbol GBT. Morgan Stanley and Goldman Sachs acted as lead managers on the deal.